Kenvue Inc. (KVUE)
| Market Cap | 32.95B |
| Revenue (ttm) | 15.01B -2.9% |
| Net Income | 1.43B +34.7% |
| EPS | 0.75 +35.3% |
| Shares Out | 1.92B |
| PE Ratio | 23.00 |
| Forward PE | 15.97 |
| Dividend | $0.83 (4.79%) |
| Ex-Dividend Date | Feb 11, 2026 |
| Volume | 42,654,978 |
| Open | 17.38 |
| Previous Close | 17.34 |
| Day's Range | 17.18 - 17.44 |
| 52-Week Range | 14.02 - 25.17 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 20.00 (+16.28%) |
| Earnings Date | Feb 6, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 16.28% from the latest price.
News
Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue
Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is pa...
Kimberly-Clark Posts Higher Profit Ahead of Kenvue Vote
Kimberly-Clark reported a higher profit in its latest quarter just days before shareholders vote on its plan to buy Kenvue, a deal designed to create a global health-and-wellness giant.
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Paracetamol/Tylenol in pregnancy is safe, says research prompted by Trump autism claims
Taking paracetamol, known as Tylenol in the U.S., during pregnancy is safe, a group of European researchers have said, after compiling data in response to U.S. President Donald Trump's claims of a lin...
ISS recommends shareholders approve Kimberly-Clark's planned Kenvue deal
Institutional Shareholder Services on Friday recommended that shareholders approve plans by Kleenex maker Kimberly-Clark to buy Tylenol maker Kenvue, saying a tie-up could improve financial metri...
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
Dividend Kings: 3 Ideal Buys In 56 For December
Dividend Kings remain largely overvalued, but six—including MO, UVV, HRL, KVUE, CDUAF, and UBSI—are now fairly priced with yields (from $1k invested) exceeding share prices. Analyst forecasts project ...
GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities
The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to re...
Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500
S&P 500 high-yield 'safer' dividend stocks offer attractive upside, with twelve currently meeting the dogcatcher ideal of dividends exceeding share prices. Analyst targets forecast 21.14% to 44.05% ne...
Macquarie Value Fund Q3 2025 Contributors And Detractors
Kenvue Inc. (KVUE), a maker of consumer health products including pain reliever Tylenol, was a notable detractor. Information technology services provider Fidelity National Information Services Inc. (...
Kenvue: Worth Owning As Kimberly-Clark Deal Plays Out
Kimberly-Clark is acquiring Kenvue in a $48.7 billion cash-and-stock deal. I believe the deal is likely to close, and that Kenvue stock gives folks a decent way to buy Kimberly-Clark at a discount. Th...
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this cust...
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
American Century Mid Cap Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. Shares of Henry Schein declined as p...
US appeals court to weigh reviving cases over Tylenol and autism
A U.S. appeals court is expected to hear arguments on Monday from families seeking to revive their lawsuits over Tylenol, after the Trump administration publicly promoted their claims that the popular...
Texas state judge won't block Kenvue from paying dividend, company lawyer says
A Texas state judge won't block Kenvue from paying its scheduled November 26 shareholder dividend, rejecting a request by Texas Attorney General Ken Paxton, a Kenvue lawyer told Reuters on Friday.
Judge to weigh if Texas AG can block Kenvue dividend over Tylenol
A Texas judge on Friday will consider state Attorney General Ken Paxton's bid to block Kenvue from paying a $398 million dividend to shareholders and from marketing Tylenol as safe for pregnant women.
Texas seeks to block Kenvue dividend amid Tylenol lawsuit
Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing ...
Watch These Stocks Falling 10% Or More
Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) su...
Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue
Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred r...
The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker
Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump ...